PT - JOURNAL ARTICLE AU - Wei, Congwen AU - Wan, Luming AU - Zhang, Yanhong AU - Fan, Chen AU - Yan, Qiulin AU - Yang, Xiaoli AU - Gong, Jing AU - Yang, Huan AU - Li, Huilong AU - Zhang, Jun AU - Zhang, Zhe AU - Wang, Rong AU - Wang, Xiaolin AU - Sun, Jin AU - Zong, Yulong AU - Yin, Feng AU - Gao, Qi AU - Cao, Yuan AU - Zhong, Hui TI - Cholesterol Metabolism — Impact for SARS-CoV-2 Infection Prognosis, Entry, and Antiviral Therapies AID - 10.1101/2020.04.16.20068528 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.16.20068528 4099 - http://medrxiv.org/content/early/2020/04/22/2020.04.16.20068528.short 4100 - http://medrxiv.org/content/early/2020/04/22/2020.04.16.20068528.full AB - The recently emerged pathogenic SARS-coronavirus 2 (SARS-CoV-2) has spread rapidly, leading to a global pandemic. Identification of risk factors for morbidity and cellular coreceptors for SARS-CoV-2 entry is thus urgently needed. In this study, we performed a retrospective study involving 861 patients with COVID-19 from a single-center classified as mild, moderate, severe or critical and found that SARS-CoV-2 infection was associated with clinically significant lower levels of cholesterol. The levels of both TC and HDL were inversely associated with the severity of SARS-CoV-2 infection. In addition, in patients with severe disease, a significant increase in the serum HDL level was correlated with good outcomes. We also showed that a clinically approved HDLR antagonist inhibited SARS-CoV-2 pseudovirus infection. Notably, SARS-2-S bound to cholesterol. Our results not only identify the HDL level as a prognostic marker for SARS-CoV-2 infection but also indicate a potential target for antiviral intervention.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is a single center based retrospective study, not a clinical trialFunding StatementThis study was supported in part by grants from the National Key Research and Development Program of China (2018YFA0900800) and the National Natural Science Foundation of China (31670761, 31872715 and 81773205).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data, models, or code generated or used during the study are available from the corresponding author by request.